Holen Sie sich die Stockscreener-App
168.76
1.84%
-3.17
Handel nachbörslich:
168.16
-0.60
-0.36%
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Belite Bio CEO Lin Yu-Hsin sells $1.66m in shares - Investing.com India
Belite Bio (BLTE) CEO Lin Yu-Hsin sells 9,200 ADS in planned trade - Stock Titan
Belite Bio (BLTE) director sells 1,100 ADS via Rule 10b5-1 plan - Stock Titan
Belite Bio (BLTE) CFO sells 6,200 ADS under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Belite Bio stock rating at buy By Investing.com - Investing.com Australia
Belite Bio (BLTE) Eps Diluted (TTM) - Zacks Investment Research
BLTE (NASDAQ) files Form 144 listing ADS sales and vesting activity - Stock Titan
[144] BELITE BIO, INC SEC Filing - Stock Titan
Belite Bio (NASDAQ: BLTE) lists 1,400 and 8,796 shares from option exercises - Stock Titan
(BLTE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Benchmark reaffirms Belite Bio stock rating on cash position, trial progress - Investing.com Canada
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - Defense World
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - tipranks.com
Belite Bio (BLTE) Is Up 7.9% After Phase 3 DRAGON Win And $402M OfferingHas The Bull Case Changed? - Sahm
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO now holds 289,736 vested option shares - Stock Titan
Belite Bio (BLTE) CSO gains 144,868-share option vesting - Stock Titan
Belite Bio Jumps on Drug Hopes and Analyst Boost - TipRanks
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - TipRanks
Belite Bio, Inc. ADR Shares Surge on Drug Progress - tipranks.com
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - The Manila Times
Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online - Stock Titan
Belite Bio (BLTE) 2025 20-F: Tinlarebant NDA plan and rising losses - stocktitan.net
Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - Barchart.com
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat
(BLTE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan
Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan
Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan
Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan
BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan
Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan
Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan
Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan
Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan
(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily
Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio at Leerink Conference: Tinlarebant’s Promising Trials - Investing.com
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat
Belite Bio, Inc. ADR (BLTE) Receives a Buy from Maxim Group - The Globe and Mail
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):